https://orcid.org/0000-0002-5397-3493
About the Authors
- Richard Allman
-
Contributed equally to this work with: Richard Allman, John L. Hopper
Roles Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing
* E-mail: richard.allman@gtglabs.com
Affiliations Genetic Technologies / Phenogen Sciences, Fitzroy, Australia, Centre for Epidemiology and Biostatistics, The University of Melbourne, Parkville, VIC, Australia
- Erika Spaeth
-
Roles Formal analysis, Visualization, Writing – review & editing
¶‡ ES, JL and SJG also contributed equally to this work.
Affiliation Phenogen Sciences, Charlotte, North Carolina, United States of America
- John Lai
-
Roles Data curation, Formal analysis, Investigation, Writing – review & editing
¶‡ ES, JL and SJG also contributed equally to this work.
Affiliations Genetic Technologies / Phenogen Sciences, Fitzroy, Australia, Centre for Epidemiology and Biostatistics, The University of Melbourne, Parkville, VIC, Australia
- Susan J. Gross
-
Roles Conceptualization, Methodology, Supervision, Writing – review & editing
Current address: Icahn School of Medicine at Mount Sinai, New York, New York, United States of America
¶‡ ES, JL and SJG also contributed equally to this work.
Affiliation Phenogen Sciences, Charlotte, North Carolina, United States of America
- John L. Hopper
-
Contributed equally to this work with: Richard Allman, John L. Hopper
Roles Conceptualization, Formal analysis, Investigation, Methodology, Supervision, Visualization, Writing – review & editing
Affiliation Centre for Epidemiology and Biostatistics, The University of Melbourne, Parkville, VIC, Australia
Competing Interests
RA and ES are current employees of Genetic Technologies Ltd. JL and SG were previous employees of Genetic technologies Ltd. This study was fully funded by Genetics Technologies Ltd. The risk model analysed in the present study is, or has been, commercially available under the tradename BREVAGenplus®. The product is covered by provisional patent application AU2018213400. This does not alter our adherence to PLOS ONE policies on sharing data and materials.